AOP-Wiki

AOP ID and Title:

AOP 345: Androgen receptor (AR) antagonism leading to decreased fertility in females
Short Title: AR antagonism leading to decreased fertility

Graphical Representation

Authors

Eleftheria-Maria Panagiotou; Karolinska Institutet and Karolinska University Hospital, SE-14186 Stockholm, Sweden

Pauliina Damdimopoulou; Karolinska Institutet and Karolinska University Hospital, SE-14186 Stockholm, Sweden

Terje Svingen; National Food Institute, Technical University of Denmark, Kongens Lyngby, 2800 Denmark

Status

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development 1.109 Included in OECD Work Plan

Abstract

The proposed AOP (Figure 2) links AR antagonism (MIE26) to ovarian cycle irregularities (KE405) and reduced female fertility (KE406) via three key events: decreased AR activity (KE1614), altered AR gene transcription (KE286), and reduced granulosa cell proliferation (KE1800). Briefly, the binding of an antagonist to the AR prevents receptor activation and subsequent transcriptional regulation, ultimately disrupting expression of AR target genes necessary for follicle growth. This attenuates granulosa cell proliferation, leading to changes in the follicle population, which again disrupts the finely tuned ovarian cycle leading to subfertility.

 

The six KEs span a selected causal pathway between direct AR antagonism and reduced fertility in females. The first three KEs describe the essential component linking a chemical’s direct interaction with the AR preventing normal ligand binding and receptor activation, leading to altered AR-regulated gene transcription in target cells and tissues in complex in vivo systems (Draskau et al 2024, accepted). The first two KEs may have broad taxonomic applicability, whereas KE286 serves as a placeholder KE for tissue/organ-specific changes in gene regulation; for this AOP the ovaries.

Decreased AR activity described in KE1614 can result from several upstream events, notably lower androgen levels, or as presented in this AOP, from AR antagonism (KE26). KE26 can be easily measured in vitro either by using reporter gene assays or by monitoring AR dimerization and nucleus translocation, both essential for the canonical AR pathway. KE1614 is not measured directly in mammals, but an assay in fish, the RADAR assay, is available.

Although AR can have both non-genomic and genomic actions, we have focussed on the canonical genomic actions in this AOP, including KE286 which refers to altered expression of AR-target genes. In principle, KE286 can describe the transcriptional changes in specific organs or tissues at specific life stages in response to AR antagonism, which will be specific for whichever AO it leads to. There is currently no standardized method for measuring this KE; however, standard methods such as reverse transcription-quantitative PCR (RT-qPCR) or RNA sequencing can be employed.

The fourth KE, ‘reduced granulosa cell proliferation’(KE1800), represents an ovary-specific outcome of reduced AR signaling which integrates several known signaling pathways, such as PI3K/Akt, but also kit-ligand (Kitl) and growth differentiation factor 9 (Gdf9) that all may be under the control of the AR in the granulosa cells (Shiina et al., 2006). With the many pathways potentially involved in granulosa cell proliferation, they are challenging to measure in isolation, hence cell proliferation was considered the most pragmatic KE leading to disrupted  pathway progression. KE1800 can be measured in vitro by proliferation assays using commercially available granulosa-like cell lines. Granulosa cell proliferation manifests as follicle growth, therefore counting and assessing the growth stage of follicles is the currently standardized method to measure this KE in vivo. Follicle growth can also be assessed with detection of proliferation markers in situ, albeit not currently included in test guidelines.

KE405 relates to ovarian cycle irregularities, encompassing variations in cycle length and/or ovulation problems (deferred ovulation or anovulation). These irregularities indicate disturbances in any parts of the Hypothalamic-Pituitary-Ovarian (HPO) axis, which regulates reproductive processes. Therefore, we have considered KE405 as an AO. It can be measured in vivo by estrous cycle monitoring, an endpoint in several guideline tests. Lastly, the AO on impaired female fertility refers to the capacity to conceive and is measured by calculating fertility rate based on born offspring numbers.

Summary of the AOP

Events

Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)

Sequence Type Event ID Title Short name
MIE 26 Antagonism, Androgen receptor Antagonism, Androgen receptor
KE 1614 Decrease, androgen receptor activation Decrease, AR activation
KE 286 Altered, Transcription of genes by the androgen receptor Altered, Transcription of genes by the AR
KE 1800 Granulosa cell proliferation of gonadotropin-independent follicles, Reduced Reduced granulosa cell proliferation
AO 405 disrupted, ovarian cycle disrupted, ovarian cycle
AO 406 decreased, Fertility decreased, Fertility

Key Event Relationships

Upstream Event Relationship Type Downstream Event Evidence Quantitative Understanding
Antagonism, Androgen receptor adjacent Decrease, androgen receptor activation
Decrease, androgen receptor activation adjacent Altered, Transcription of genes by the androgen receptor
Altered, Transcription of genes by the androgen receptor adjacent Granulosa cell proliferation of gonadotropin-independent follicles, Reduced Moderate Low
Granulosa cell proliferation of gonadotropin-independent follicles, Reduced adjacent disrupted, ovarian cycle
disrupted, ovarian cycle adjacent decreased, Fertility High Low

Stressors

Name Evidence
Flutamide Moderate

Overall Assessment of the AOP

Weight of evidence assessment is conducted for the AOP overall to establish the confidence in the causal relationships between linked KEs. Using modified Bradford-Hill criteria, we subjectively rated the overall confidence in AOP345 as ‘moderate’, with the weakest link, relative to scientific evidence, being KER2273.

Domain of Applicability

Life Stage Applicability
Life Stage Evidence
Adult, reproductively mature High
Taxonomic Applicability
Term Scientific Term Evidence Links
mammals mammals High NCBI
Sex Applicability
Sex Evidence
Female High

The domain of applicability of an AOP is defined by the most narrowly restricted of its KE(R)s. In this AOP, the early KEs have a broad domain of applicability that includes all ages and sexes within vertebrates, although they have been developed currently for mammalian species. The adverse outcomes of this AOP narrow the applicability domain to females of reproductive age with evidence currently from mainly rodent studies but also humans, non-human primates, and livestock animals.

Essentiality of the Key Events

Direct evidence for all included KEs is provided from studies where KE upstream is blocked and an effect on KE downstream is observed. However, one of the strongest pieces of evidence for this AOP comes from ARKO mouse models where all of the downstream KEs can be observed. Global ARKO models demonstrate altered gene expression, whereas granulosa cell-specific ARKO models demonstrate reduced granulosa cell proliferation, ovarian cycle irregularities and subfertility (Sen & Hammes, 2010; Walters et al., 2012). The essentiality of all KEs was assessed as high (Table 1).

Weight of Evidence Summary

We have classified the strength of each KER based on the modified Bradford-Hill criteria, by rating their biological plausibility, empirical support and essentiality of downstream KEs as ‘high’, ‘moderate’, or ‘low’ according to the instructions in OECD’s Guidance Document for Developing and Assessing AOPs.

 

Table 1. The strength of each KER was assessed using the modified Bradford-Hill criteria. The biological plausibility for each KER, empirical support, and essentiality of the downstream KE were assessed and assigned as ‘high’ or ‘moderate’. No criterion was assigned as ‘low’ strength within the proposed AOP. Biological plausibility was deemed ‘high’ in cases of established mechanistic basis and ‘moderate’ when mechanistic understanding was incomplete. For essentiality, direct evidence exists for all included KEs where AR antagonists and ARKO models show that downstream KEs are impacted. Empirical support was deemed ‘high’ when there was consistent evidence using a wide range of stressors and as moderate in the case of a limited range of stressors.

 

Criteria

KER2130

KER2124

KER2273

KER3142

KER394

Biological Plausibility

HIGH

 

HIGH

 

MODERATE

 

HIGH

HIGH

Essentiality of downstream KEs

HIGH

(KE1614)

HIGH

(KE286)

HIGH

(KE1800)

HIGH

(KE405)

HIGH

(KE406)

Empirical support

HIGH

HIGH

MODERATE

 

HIGH

HIGH

 

For the KERs in which systematic and semi-systematic literature search approaches were employed (KER2273 and KER3142 respectively), additional quality control was performed. The exposure studies used as empirical evidence for each KER were assessed for their quality using the online tool SciRAP (Science in Risk Assessment and Policy, scirap.org) (Molander et al., 2015). SciRAP provided predetermined criteria for reporting and methodological quality for in vitro and in vivo studies. In this case, a simple approach using the score outcome was used to assign studies to different reliability categories, as listed in Table 2. Studies with methodological scores of more than 80% were categorized as reliable without restriction. Studies with scores below that cutoff but above 65% were classified as reliable with restriction. In Table 2, the scores of all assessed studies within one KER have been averaged.  The scores of individual studies can be found in Supplementary material. Based on the reliability category assigned from the SciRAP evaluation and the empirical support strength of the non-canonical knowledge KER2273, we concluded that the overall confidence in the KER was ‘moderate’.

 

Table 2. Average reporting and methodological quality score of exposure studies used as empirical evidence to support KERs. Based on the methodological score the overall reliability was assessed.

 

KER ID

Average reporting quality score

Average methodological quality score

Reliability category

2273

77

76

Reliable with restrictions

3142

71

81

Reliable without restrictions

Quantitative Consideration

The quantitative understanding of this AOP is limited, particularly regarding all KERs beyond the initial one, consequently categorizing it as low.

Considerations for Potential Applications of the AOP (optional)

Female reproductive disorders are on the rise and there is increasing evidence supporting a role for exposure to environmental chemicals, not least EDCs (Johansson et al., 2017). Despite this proposed causal relationship, there is still a lack of sensitive endpoints and understanding of causal mechanisms. This AOP addresses a knowledge gap as far as EDC identification is concerned, by providing an analytically constructed causal pathway linking disrupted androgen signaling with ovarian dysfunction and reduced fertility in females. Importantly, most KEs of the pathway include methods for effect measurements, which can support causal inference between in vitro data and adverse effects in an intact organism.

AOP345 also highlight gaps in knowledge and assay capacity, which can encourage the development of new approach methodologies (NAMs) to aid with chemical testing and regulation. Furthermore, it highlights the importance of ovarian follicle counts as an endpoint that currently is only optional in OECD test guidelines. Notably, however, follicle counting is a subjective, time-consuming and labor-intensive endpoint to measure, thus replacing it with a method assessing granulosa cell proliferation could be valuable. Such a method could potentially compliment estrus cycle monitoring, an endpoint that is potentially affected by different experimental set-ups, for example group size, study length and statistical analyses. AOP345 therefore offers a promising approach to address these methodological challenges. Finally, as quantitative understanding of this AOP continues to develop, it can provide a standardized methodology for assessing chemical effects and guide future regulatory decisions for the complex endpoint of female fertility.

References

Campana, C., Pezzi, V., & Rainey, W. E. (2015). Cell-based assays for screening androgen receptor ligands. Seminars in Reproductive Medicine, 33(3), 225. https://doi.org/10.1055/S-0035-1552989

Chamberlain, N. L., Driverand, E. D., & Miesfeldi, R. L. (1994). The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. In Nucleic Acids Research(Vol. 22, Issue 15).

Franks, S., & Hardy, K. (2018). Androgen action in the ovary. In Frontiers in Endocrinology (Vol. 9, Issue AUG, p. 452). Frontiers Media S.A. https://doi.org/10.3389/fendo.2018.00452

Hickey, T., Chandy, A., & Norman, R. J. (2002). The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 87(1), 161–165. https://doi.org/10.1210/jcem.87.1.8137

Jiang, X., Teng, Y., Chen, X., Liang, N., Li, Z., Liang, D., & Wu, L. (2020). Six novel Mutation analysis of the androgen receptor gene in 17 Chinese patients with androgen insensitivity syndrome. Clinica Chimica Acta, 506, 180–186. https://doi.org/10.1016/j.cca.2020.03.036

Johansson, H. K. L., Svingen, T., Fowler, P. A., Vinggaard, A. M., & Boberg, J. (2017). Environmental influences on ovarian dysgenesis-developmental windows sensitive to chemical exposures. In Nature Reviews Endocrinology (Vol. 13, Issue 7, pp. 400–414). Nature Publishing Group. https://doi.org/10.1038/nrendo.2017.36

Lee, S. H., Hong, K. Y., Seo, H., Lee, H. S., & Park, Y. (2021). Mechanistic insight into human androgen receptor-mediated endocrine-disrupting potentials by a stable bioluminescence resonance energy transfer-based dimerization assay. Chemico-Biological Interactions, 349, 109655. https://doi.org/10.1016/J.CBI.2021.109655

Lim, J. J., Han, C. Y., Lee, D. R., & Tsang, B. K. (2017). Ring Finger Protein 6 Mediates Androgen-Induced Granulosa Cell Proliferation and Follicle Growth via Modulation of Androgen Receptor Signaling. Endocrinology, 158(4), 993–1004. https://doi.org/10.1210/en.2016-1866

Lim, J. J., Lima, P. D. A., Salehi, R., Lee, D. R., & Tsang, B. K. (2017). Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome. Scientific Reports, 7(1), 10272. https://doi.org/https://dx.doi.org/10.1038/s41598-017-09880-0

Lledó, B., Llácer, J., Turienzo, A., Ortiz, J. A., Guerrero, J., Morales, R., Ten, J., & Bernabeu, R. (2014). Androgen receptor CAG repeat length is associated with ovarian reserve but not with ovarian response. Reproductive BioMedicine Online, 29, 509–515. https://doi.org/10.1016/j.rbmo.2014.06.012

Molander, L., Ågerstrand, M., Beronius, A., Hanberg, A., & Rudén, C. (2015). Science in Risk Assessment and Policy (SciRAP): An Online Resource for Evaluating and Reporting In Vivo (Eco)Toxicity Studies. Human and Ecological Risk Assessment, 21(3), 753–762. https://doi.org/10.1080/10807039.2014.928104

OECD. (2020). Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals. In OECD Guidelines for the Testing of Chemicals, Section 4 (OECD Guide). OECD Publishing. https://doi.org/10.1787/9789264264366-en

OECD. (2022). Test No. 251: Rapid Androgen Disruption Activity Reporter (RADAR) assay. OECD Publishing. https://doi.org/10.1787/da264d82-en

Panagiotou, E. M., Draskau, M. K., Li, T., Hirschberg, A., Svingen, T., & Damdimopoulou, P. (2022). AOP key event relationship report: Linking decreased androgen receptor activation with decreased granulosa cell proliferation of gonadotropin-independent follicles. Reproductive Toxicology, 112, 136–147. https://doi.org/10.1016/j.reprotox.2022.07.004

Sen, A., & Hammes, S. R. (2010). Granulosa Cell-Specific Androgen Receptors Are Critical Regulators of Ovarian Development and Function. Molecular Endocrinology, 24(7), 1393–1403. https://doi.org/10.1210/me.2010-0006

Shiina, H., Matsumoto, T., Sato, T., Igarashi, K., Miyamoto, J., Takemasa, S., Sakari, M., Takada, I., Nakamura, T., Metzger, D., Chambon, P., Kanno, J., Yoshikawa, H., & Kato, S. (2006). Premature ovarian failure in androgen receptor-deficient mice. In PNAS (Vol. 103, Issue 1). www.pnas.orgcgidoi10.1073pnas.0506736102

Svingen, T., Villeneuve, D. L., Knapen, D., Panagiotou, E. M., Draskau, M. K., Damdimopoulou, P., & O’Brien, J. M. (2021). A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation. Toxicological Sciences, 184(2), 183–190. https://doi.org/10.1093/TOXSCI/KFAB113

Tut, T. G., Ghadessy, F. J., Trifiro, M. A., Pinsky, L., & Yong, E. L. (1997). Long Polyglutamine Tracts in the Androgen Receptor Are Associated with Reduced Trans-Activation, Impaired Sperm Production, and Male Infertility*. In J Clin Endocrinol Metab (Vol. 82). https://academic.oup.com/jcem/article/82/11/3777/2866074

Walters, K. A., Middleton, L. J., Joseph, S. R., Hazra, R., Jimenez, M., Simanainen, U., Allan, C. M., & Handelsman, D. J. (2012). Targeted loss of androgen receptor signaling in murine granulosa cells of preantral and antral follicles causes female subfertility. Biology of Reproduction, 87(6). https://doi.org/10.1095/biolreprod.112.102012

Appendix 1

List of MIEs in this AOP

Event: 26: Antagonism, Androgen receptor

Short Name: Antagonism, Androgen receptor

Key Event Component

Process Object Action
androgen receptor activity androgen receptor decreased

AOPs Including This Key Event

Stressors

Name
Mercaptobenzole
Triticonazole
Flusilazole
Epoxiconazole
Prochloraz
Propiconazole
Tebuconazole
Flutamide
Cyproterone acetate
Vinclozolin

Biological Context

Level of Biological Organization
Molecular

Cell term

Cell term
eukaryotic cell

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
mammals mammals High NCBI
Life Stage Applicability
Life Stage Evidence
During development and at adulthood High
Sex Applicability
Sex Evidence
Mixed High

Both the DNA-binding and ligand-binding domains of the AR are highly evolutionary conserved, whereas the transactivation domain show more divergence which may affect AR-mediated gene regulation across species (Davey & Grossmann, 2016). Despite certain inter-species differences, AR function mediated through gene expression is highly conserved, with mutations studies from both humans and rodents showing strong correlation for AR-dependent development and function (Walters et al, 2010). 

This KE is applicable for both sexes, across developmental stages into adulthood, in numerous cells and tissues and across mammalian taxa. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Description

The androgen receptor (AR) and its function

The AR is a ligand-activated transcription factor belonging to the steroid hormone nuclear receptor family (Davey & Grossmann, 2016). The AR has three domains: the N-terminal domain, the DNA-binding domain and the ligand-binding domain, with the latter being most evolutionary conserved. Testosterone (T) and the more biologically active dihydrotestosterone (DHT) are endogenous ligands for the AR (MacLean et al, 1993; MacLeod et al, 2010; Schwartz et al, 2019). In teleost fishes, 11-ketotestosterone is the second main ligand (Schuppe et al, 2020). Human AR mutations and mouse knock-out models have established a pivotal role for the AR in masculinization and spermatogenesis (Walters et al, 2010). Apart from the essential role for AR in male reproductive development and function (Walters et al, 2010), the AR is also expressed in many other tissues and organs such as bone, muscles, ovaries, and the immune system (Rana et al, 2014). 

AR antagonism as Key Event

The main function of the AR is to activate gene transcription in cells. Canonical signaling occurs by ligands (androgens) binding to AR in the cytoplasm which results in translocation to the cell nucleus, receptor dimerization and binding to specific regulatory DNA sequences (Heemers & Tindall, 2007). The gene targets regulated by AR activation depends on cell/tissue type and what stage of development activation occur, and is, for instance, dependent on available co-factors. Apart from the canonical signaling pathway, AR can also initiate cytoplasmic signaling pathways with other functions than the nuclear pathway, for instance rapid change in cell function by ion transport changes (Heinlein & Chang, 2002) and association with Src kinase to activate MAPK/ERK signaling and activation of the PI3K/Akt pathway (Leung & Sadar, 2017)

How it is Measured or Detected

AR antagonism can be measured in vitro by transient or stable transactivation assays to evaluate nuclear receptor activation. There is already a validated test guideline for AR (ant)agonism adopted by the OECD, Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals (OECD, 2016). This test guideline contains three different methods. More information on limitations, advantages, protocols, and availability and description of cells are given in the test guideline.

Besides these validated methods, other transiently or stably transfected reporter cell lines are available as well as yeast based systems (Campana et al, 2015; Körner et al, 2004). AR nuclear translocation can be monitored by various assays (Campana et al 2015), for example by monitoring fluorescent rat AR movement in living cells (Tyagi et al 2020), with several human AR translocation assays being commercially available; e.g. Fluorescent AR Nuclear Translocation Assay (tGFP-hAR/HEK293) or Human Androgen NHR Cell Based Antagonist Translocation LeadHunter Assay.

Additional information on AR interaction can be obtained employing competitive AR binding assays (Freyberger et al 2010, Shaw et al 2018), which can also inform on relative potency of the compounds, though not on downstream effect of the AR binding.

The recently developed AR dimerization assay provides an assay with an improved ability to measure potential stressor-mediated disruption of dimerization/activation (Lee et al, 2021).

References

Campana C, Pezzi V, Rainey WE (2015) Cell based assays for screening androgen receptor ligands. Semin Reprod Med 33: 225-234.

Davey RA, Grossmann M (2016) Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev 37: 3-15

Freyberger A, Weimer M, Tran HS, Ahr HJ. Assessment of a recombinant androgen receptor binding assay: initial steps towards validation. Reprod Toxicol. 2010 Aug;30(1):2-8. doi: 10.1016/j.reprotox.2009.10.001. Epub 2009 Oct 13. PMID: 19833195.

Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808

Heinlein CA, Chang C (2002) The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16: 2181-2187

Körner W, Vinggaard AM, Térouanne B, Ma R, Wieloch C, Schlumpf M, Sultan C, Soto AM (2004) Interlaboratory comparison of four in vitro assays for assessing androgenic and antiandrogenic activity of environmental chemicals. Environ Health Perspect 112: 695-702

Lee SH, Hong KY, Seo H, Lee HS, Park Y (2021) Mechanistic insight into human androgen receptor-mediated endocrine-disrupting potentials by a stable bioluminescence resonance energy transfer-based dimerization assay. Chem Biol Interact 349: 109655

Leung, J. K., & Sadar, M. D. (2017). Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Frontiers in Endocrinology, 8. https://doi.org/10.3389/fendo.2017.00002

MacLean HE, Chu S, Warne GL, Zajac JD (1993) Related individuals with different androgen receptor gene deletions. J Clin Invest 91: 1123-1128

MacLeod DJ, Sharpe RM, Welsh M, Fisken M, Scott HM, Hutchison GR, Drake AJ, van den Driesche S (2010) Androgen action in the masculinization programming window and development of male reproductive organs. Int J Androl 33: 279-287

OECD. (2016) Test No. 458: Stably Transfected Human Androgen Receptor Transcriptional Activation Assay for Detection of Androgenic Agonist and Antagonist Activity of Chemicals. OECD Guidelines for the Testing of Chemicals, Section 4, Paris.

OECD (2022). Test No. 251: Rapid Androgen Disruption Activity Reporter (RADAR) assay. Paris: OECD Publishing doi:10.1787/da264d82-en.

Rana K, davey RA, Zajac JD (2014) Human androgen deficiency: insights gained from androgen receptor knockout mouse models. Asian J Androl 16: 169-177

Satoh K, Ohyama K, Aoki N, Iida M, Nagai F (2004) Study on anti-androgenic effects of bisphenol a diglycidyl ether (BADGE), bisphenol F diglycidyl ether (BFDGE) and their derivatives using cells stably transfected with human androgen receptor, AR-EcoScreen. Food Chem Toxicol 42: 983-993

Schuppe, E. R., Miles, M. C., and Fuxjager, M. J. (2020). Evolution of the androgen receptor: Perspectives from human health to dancing birds. Mol. Cell. Endocrinol. 499, 110577. doi:10.1016/J.MCE.2019.110577 

Schwartz CL, Christiansen S, Vinggaard AM, Axelstad M, Hass U, Svingen T (2019) Anogenital distance as a toxicological or clinical marker for fetal androgen action and risk for reproductive disorders. Arch Toxicol 93: 253-272

Shaw J, Leveridge M, Norling C, Karén J, Molina DM, O'Neill D, Dowling JE, Davey P, Cowan S, Dabrowski M, Main M, Gianni D. Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay. Sci Rep. 2018 Jan 9;8(1):163. doi: 10.1038/s41598-017-18650-x. PMID: 29317749; PMCID: PMC5760633.

Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, Roy AK (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol Endocrinol 14: 1162-1174

Walters KA, Simanainen U, Handelsman DJ (2010) Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 16: 543-558

List of Key Events in the AOP

Event: 1614: Decrease, androgen receptor activation

Short Name: Decrease, AR activation

AOPs Including This Key Event

Biological Context

Level of Biological Organization
Tissue

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
mammals mammals High NCBI
Life Stage Applicability
Life Stage Evidence
During development and at adulthood High
Sex Applicability
Sex Evidence
Mixed High

This KE is considered broadly applicable across mammalian taxa as all mammals express the AR in numerous cells and tissues where it regulates gene transcription required for developmental processes and functions. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Description

This KE refers to decreased activation of the androgen receptor (AR) as occurring in complex biological systems such as tissues and organs in vivo. It is thus considered distinct from KEs describing either blocking of AR or decreased androgen synthesis.

The AR is a nuclear transcription factor with canonical AR activation regulated by the binding of the androgens such as testosterone or dihydrotestosterone (DHT). Thus, AR activity can be decreased by reduced levels of steroidal ligands (testosterone, DHT) or the presence of compounds interfering with ligand binding to the receptor (Davey & Grossmann, 2016; Gao et al., 2005).

In the inactive state, AR is sequestered in the cytoplasm of cells by molecular chaperones. In the classical (genomic) AR signaling pathway, AR activation causes dissociation of the chaperones, AR dimerization and translocation to the nucleus to modulate gene expression. AR binds to the androgen response element (ARE) (Davey & Grossmann, 2016; Gao et al., 2005). Notably, for transcriptional regulation the AR is closely associated with other co-factors that may differ between cells, tissues and life stages. In this way, the functional consequence of AR activation is cell- and tissue-specific. This dependency on co-factors such as the SRC proteins also means that stressors affecting recruitment of co-activators to AR can result in decreased AR activity (Heinlein & Chang, 2002).

Ligand-bound AR may also associate with cytoplasmic and membrane-bound proteins to initiate cytoplasmic signaling pathways with other functions than the nuclear pathway. Non-genomic AR signaling includes association with Src kinase to activate MAPK/ERK signaling and activation of the PI3K/Akt pathway. Decreased AR activity may therefore be a decrease in the genomic and/or non-genomic AR signaling pathways (Leung & Sadar, 2017).

How it is Measured or Detected

This KE specifically focuses on decreased in vivo activation, with most methods that can be used to measure AR activity carried out in vitro. They provide indirect information about the KE and are described in lower tier MIE/KEs (see for example MIE/KE-26 for AR antagonism, KE-1690 for decreased T levels and KE-1613 for decreased dihydrotestosterone levels). In this way, this KE is a placeholder for tissue-specific responses to AR activation or inactivation that will depend on the adverse outcome (AO) for which it is included.

In fish, The Rapid Androgen Disruption Activity Reporter (RADAR) assay included in OECD test guideline no. 251 can be used to measure genomic AR activity (OECD, 2022). Employing a spg1-gfp construct under control of the AR-binding promoter spiggin1 in medaka fish embryos, any stressor activating or inhibiting the androgen axis will be detected. This includes for instance stressors that agonize or antagonize AR, as well as stressors that modulate androgen synthesis or metabolism. Non-genomic AR activity cannot be detected by the RADAR assay (OECD, 2022). Similar assays may in the future be developed to measure AR activity in mammalian organisms.  

References

Davey, R. A., & Grossmann, M. (2016). Androgen Receptor Structure, Function and Biology: From Bench to Bedside. The Clinical Biochemist. Reviews, 37(1), 3–15.

Gao, W., Bohl, C. E., & Dalton, J. T. (2005). Chemistry and structural biology of androgen receptor. Chemical Reviews, 105(9), 3352–3370. https://doi.org/10.1021/cr020456u

Heinlein, C. A., & Chang, C. (2002). Androgen Receptor (AR) Coregulators: An Overview. https://academic.oup.com/edrv/article/23/2/175/2424160

Leung, J. K., & Sadar, M. D. (2017). Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Frontiers in Endocrinology, 8. https://doi.org/10.3389/fendo.2017.00002

OECD (2022). Test No. 251: Rapid Androgen Disruption Activity Reporter (RADAR) assay. Paris: OECD Publishing doi:10.1787/da264d82-en.

 

 

Event: 286: Altered, Transcription of genes by the androgen receptor

Short Name: Altered, Transcription of genes by the AR

Key Event Component

Process Object Action
regulation of gene expression androgen receptor decreased

AOPs Including This Key Event

Stressors

Name
Bicalutamide
Cyproterone acetate
Epoxiconazole
Flutamide
Flusilazole
Prochloraz
Propiconazole
Stressor:286 Tebuconazole
Triticonazole
Vinclozalin

Biological Context

Level of Biological Organization
Tissue

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
mammals mammals High NCBI
Life Stage Applicability
Life Stage Evidence
During development and at adulthood High
Sex Applicability
Sex Evidence
Mixed High

Both the DNA-binding and ligand-binding domains of the AR are highly evolutionary conserved, whereas the transactivation domain show more divergence, which may affect AR-mediated gene regulation across species (Davey and Grossmann 2016). Despite certain inter-species differences, AR function mediated through gene expression is highly conserved, with mutation studies from both humans and rodents showing strong correlation for AR-dependent development and function (Walters et al. 2010). 

This KE is considered broadly applicable across mammalian taxa, sex and developmental stages, as all mammals express the AR in numerous cells and tissues where it regulates gene transcription required for developmental processes and function. It is, however, acknowledged that this KE most likely has a much broader domain of applicability extending to non-mammalian vertebrates. AOP developers are encouraged to add additional relevant knowledge to expand on the applicability to also include other vertebrates.

Key Event Description

This KE refers to transcription of genes by the androgen receptor (AR) as occurring in complex biological systems such as tissues and organs in vivoRather than measuring individual genes, this KE aims to capture patterns of effects at transcriptome level in specific target cells/tissues. In other words, it can be replaced by specific KEs for individual adverse outcomes as information becomes available, for example the transcriptional toxicity response in prostate tissue for AO: prostate cancer, perineum tissue for AO: reduced AGD, etc.  AR regulates many genes that differ between tissues and life stages and, importantly, different gene transcripts within individual cells can go in either direction since AR can act as both transcriptional activator and suppressor. Thus, the ‘directionality’ of the KE cannot be either reduced or increased, but instead describe an altered transcriptome.

The Androgen Receptor and its function

The AR belongs to the steroid hormone nuclear receptor family. It is a ligand-activated transcription factor with three domains: the N-terminal domain, the DNA-binding domain, and the ligand-binding domain with the latter being the most evolutionary conserved (Davey and Grossmann 2016). Androgens (such as dihydrotestosterone and testosterone) are AR ligands and act by binding to the AR in androgen-responsive tissues (Davey and Grossmann 2016). Human AR mutations and mouse knockout models have established a fundamental role for AR in masculinization and spermatogenesis (Maclean et al.; Walters et al. 2010; Rana et al. 2014). The AR is also expressed in many other tissues such as bone, muscles, ovaries and within the immune system (Rana et al. 2014).

 

Altered transcription of genes by the AR as a Key Event

Upon activation by ligand-binding, the AR translocates from the cytoplasm to the cell nucleus, dimerizes, binds to androgen response elements in the DNA to modulate gene transcription (Davey and Grossmann 2016). The transcriptional targets vary between cells and tissues, as well as with developmental stages and is also dependent on available co-regulators (Bevan and Parker 1999; Heemers and Tindall 2007). It should also be mentioned that the AR can work in other ‘non-canonial’ ways such as non-genomic signaling, and ligand-independent activation (Davey & Grossmann, 2016; Estrada et al, 2003; Jin et al, 2013).

A large number of known, and proposed, target genes of AR canonical signaling have been identified by analysis of gene expression following treatments with AR agonists (Bolton et al. 2007; Ngan et al. 2009, Jin et al. 2013).

How it is Measured or Detected

Altered transcription of genes by the AR can be measured by measuring the transcription level of known downstream target genes by RT-qPCR or other transcription analyses approaches, e.g. transcriptomics.

Since this KE aims to capture AR-mediated transcriptional patterns of effect, downstream bioinformatics analyses will typically be required to identify and compare effect footprints. Clusters of genes can be statistically associated with, for example, biological process terms or gene ontology terms relevant for AR-mediated signaling. Large transcriptomics data repositories can be used to compare transcriptional patterns between chemicals, tissues, and species (e.g. TOXsIgN (Darde et al, 2018a; Darde et al, 2018b), comparisons can be made to identified sets of AR ‘biomarker’ genes (e.g. as done in (Rooney et al, 2018)), and various methods can be used e.g. connectivity mapping (Keenan et al, 2019).

References

Bevan C, Parker M (1999) The role of coactivators in steroid hormone action. Exp. Cell Res. 253:349–356

Bolton EC, So AY, Chaivorapol C, et al (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev 21:2005–2017. doi: 10.1101/gad.1564207

Darde, T. A., Gaudriault, P., Beranger, R., Lancien, C., Caillarec-Joly, A., Sallou, O., et al. (2018a). TOXsIgN: a cross-species repository for toxicogenomic signatures. Bioinformatics 34, 2116–2122. doi:10.1093/bioinformatics/bty040.

Darde, T. A., Chalmel, F., and Svingen, T. (2018b). Exploiting advances in transcriptomics to improve on human-relevant toxicology. Curr. Opin. Toxicol. 11–12, 43–50. doi:10.1016/j.cotox.2019.02.001.

Davey RA, Grossmann M (2016) Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev 37:3–15

Estrada M, Espinosa A, Müller M, Jaimovich E (2003) Testosterone Stimulates Intracellular Calcium Release and Mitogen-Activated Protein Kinases Via a G Protein-Coupled Receptor in Skeletal Muscle Cells. Endocrinology 144:3586–3597. doi: 10.1210/en.2002-0164

Heemers H V., Tindall DJ (2007) Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 28:778–808

Jin, Hong Jian, Jung Kim, and Jindan Yu. 2013. “Androgen Receptor Genomic Regulation.” Translational Andrology and Urology 2(3):158–77. doi: 10.3978/j.issn.2223-4683.2013.09.01

Keenan, A. B., Wojciechowicz, M. L., Wang, Z., Jagodnik, K. M., Jenkins, S. L., Lachmann, A., et al. (2019). Connectivity Mapping: Methods and Applications. Annu. Rev. Biomed. Data Sci. 2, 69–92. doi:10.1146/ANNUREV-BIODATASCI-072018-021211.

Maclean HE, Chu S, Warne GL, Zajact JD Related Individuals with Different Androgen Receptor Gene Deletions

MacLeod DJ, Sharpe RM, Welsh M, et al (2010) Androgen action in the masculinization programming window and development of male reproductive organs. In: International Journal of Andrology. Blackwell Publishing Ltd, pp 279–287

Ngan S, Stronach EA, Photiou A, et al (2009) Microarray coupled to quantitative RT–PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28:2051–2063. doi: 10.1038/onc.2009.68

Rana K, Davey RA, Zajac JD (2014) Human androgen deficiency: Insights gained from androgen receptor knockout mouse models. Asian J. Androl. 16:169–177

Rooney, J. P., Chorley, B., Kleinstreuer, N., and Corton, J. C. (2018). Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium. Toxicol. Sci. 166, 146–162. doi:10.1093/TOXSCI/KFY187.

Walters KA, Simanainen U, Handelsman DJ (2010) Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 16:543–558. doi: 10.1093/humupd/dmq003

Event: 1800: Granulosa cell proliferation of gonadotropin-independent follicles, Reduced

Short Name: Reduced granulosa cell proliferation

AOPs Including This Key Event

Biological Context

Level of Biological Organization
Cellular

Cell term

Cell term
eukaryotic cell

Organ term

Organ term
ovarian follicle

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
human Homo sapiens High NCBI
mouse Mus musculus High NCBI
rat Rattus norvegicus High NCBI
Monkey Monkey High NCBI
Pig Pig High NCBI
cow Bos taurus High NCBI
Life Stage Applicability
Life Stage Evidence
During development and at adulthood High
Sex Applicability
Sex Evidence
Female High

Overview

Mechanisms controlling folliculogenesis are well conserved between mammalian species, including mice, farm animals and humans(Adhikari and Liu, 2009; McGee and Hsueh, 2000).

 

Key Event Description

Granulosa cell function

Granulosa cells of the ovary play an important structural and functional role during folliculogenesis. They form the ovarian follicle architecture and transmit molecular messages to the oocyte through gap junction channels, ensuring developmental competence(Kidder and Vanderhyden, 2010). Folliculogenesis can be roughly divided into two phases: gonadotropin-independent and gonadotropin-dependent by the requirement for the gonadotropin follicle-stimulating hormone (FSH) to grow(Hsueh et al., 2015). During the gonadotropin-independent growth phase, growth factors secreted by the follicle, e.g. growth differentiation factor-9 (GDF9) by the oocyte and anti-Müllerian hormone (AMH) by the granulosa cells control the necessary morphological changes of granulosa cells and their proliferation(Hsueh et al., 2015). The growth can be histologically observed as proliferation of the granulosa cells as the flat granulosa cells of primordial follicles become cuboidal and increase in numbers(Gougeon, 2010). The connection between granulosa cell numbers and follicle growth during gonadotropin-independent growth is well described (Gougeon and Chainy, 1987).

 

Reduced granulosa cell proliferation as Key Event

Genetically modified mouse models have demonstrated that granulosa cell proliferation is a prerequisite for normal follicle growth and fertility. For example, deletion of the oocyte-specific growth factor GDF9 that stimulates granulosa cells halt folliculogenesis at the primary follicle stage in mice: the granulosa cells fail to proliferate to generate secondary follicles, the oocytes degenerate, and the mice are sterile(Dong et al., 1996). Conversely, mice administered GDF9 have accelerated granulosa cell proliferation and higher numbers of primary and secondary follicles compared to non-treated ones(Vitt et al., 2000).

AMH is a growth factor secreted by granulosa cells during the gonadotropin-independent follicle growth stage, and it inhibits the activation of primordial follicles to keep the growing and dormant follicles in balance. In mice overexpressing AMH, follicle growth to antral stages is inhibited and the numbers of all developmental stages of follicles decline faster by age than in wildtype controls(Pankhurst et al., 2018). Exposure of human ovarian tissue to AMH in culture inhibits follicle growth(Carlsson et al., 2006).

How it is Measured or Detected

In vitro

Decreased granulosa cell proliferation can be measured in cell culture. There are commercially available human granulosa cell tumor lines, for instance KGN (#RCB1154) “Granulosa cell tumor”, available from the Riken cell Bank. This cell line is representative of undifferentiated granulosa cells at early stages of follicle development making it suitable to study interactions of primordial to early antral pathways independent from hormonal control from theca cells and hypothalamic-pituitary axis (Nishi et al., 2001).

Well-established assays to detect proliferation include methods to assess DNA synthesis (e.g. BrdU), cellular metabolism (e.g. MTT, XTT, ATP detection assays), and proliferation proteins (e.g. PCNA, Ki67, MCM-2)(Adan et al., 2016). The same methods can also be used in ovarian follicle or tissue culture.

In vivo

Granulosa cell proliferation manifests as increased numbers of granulosa cells within ovarian follicles(Gougeon and Chainy, 1987). Analysis of follicle growth is based on the numbers of granulosa cell layers which is also reflected in the diameter of the follicle(Gougeon and Chainy, 1987). Granulosa cell proliferation is inseparably connected to folliculogenesis, and therefore numbers of follicles in different developmental stages reflect the proliferation of granulosa cells. Granulosa cell proliferation can therefore be measured by counting follicles in different stages (primordial, primary, secondary) or by measuring the follicle diameters. Changes in the proliferation of granulosa cells during the early follicle growth phase would lead to altered proportions of follicles in different stages. For example, inhibition of granulosa cell proliferation can lead to reduced numbers of secondary follicles(Dong et al., 1996; Pankhurst et al., 2018). Therefore, studying ratios between follicles in different developmental stages can reveal changes in the proliferation of granulosa cells. Follicle counts are already suggested endpoints in the Extended One-Generation Reproductive Toxicity Study; EOGRTS (OECD 443)(2018).

References

Adan, A., Kiraz, Y., and Baran, Y. (2016). Cell Proliferation and Cytotoxicity Assays. Current Pharmaceutical Biotechnology 17, 1213–1221. https://doi.org/10.2174/1389201017666160808160513.

Adhikari, D., and Liu, K. (2009). Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocrine Reviews 30, 438–464. https://doi.org/10.1210/er.2008-0048.

Carlsson, I.B., Scott, J.E., Visser, J.A., Ritvos, O., Themmen, A.P.N., and Hovatta, O. (2006). Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Human Reproduction 21, 2223–2227. https://doi.org/10.1093/humrep/del165.

Dong, J., Albertini, D.F., Nishimori, K., Kumar, T.R., Lu, N., and Matzuk, M.M. (1996). Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 383, 531–535. https://doi.org/10.1038/383531a0.

Gougeon, A. (2010). Croissance folliculaire dans l’ovaire humain: de l’entrée en croissance du follicule primordial jusqu’à la maturation préovulatoire. Annales d’Endocrinologie 71, 132–143. https://doi.org/10.1016/j.ando.2010.02.021.

Gougeon, A., and Chainy, G.B.N. (1987). Morphometric studies of small follicles in ovaries of women at different ages. Journal of Reproduction and Fertility 81, 433–442. https://doi.org/10.1530/jrf.0.0810433.

Hsueh, A.J.W., Kawamura, K., Cheng, Y., and Fauser, B.C.J.M. (2015). Intraovarian control of early folliculogenesis. Endocrine Reviews 36, 1–24. https://doi.org/10.1210/er.2014-1020.

Kidder, G.M., and Vanderhyden, B.C. (2010). Bidirectional communication between oocytes and follicle cells: Ensuring oocyte developmental competence. Canadian Journal of Physiology and Pharmacology 88, 399–413. https://doi.org/10.1139/Y10-009.

McGee, E.A., and Hsueh, A.J.W. (2000). Initial and Cyclic Recruitment of Ovarian Follicles*. Endocrine Reviews 21, 200–214. https://doi.org/10.1210/edrv.21.2.0394.

Nishi, Y., Yanase, T., Mu, Y.-M., Oba, K., Ichino, I., Saito, M., Nomura, M., Mukasa, C., Okabe, T., Goto, K., et al. (2001). Establishment and Characterization of a Steroidogenic Human Granulosa-Like Tumor Cell Line, KGN, That Expresses Functional Follicle-Stimulating Hormone Receptor. Endocrinology 142, 437–445. https://doi.org/10.1210/endo.142.1.7862.

Pankhurst, M.W., Kelley, R.L., Sanders, R.L., Woodcock, S.R., Oorschot, D.E., and Batchelor, N.J. (2018). Anti-Müllerian hormone overexpression restricts preantral ovarian follicle survival. Journal of Endocrinology 237, 153–163. https://doi.org/10.1530/JOE-18-0005.

Vitt, U.A., McGee, E.A., Hayashi, M., and Hsueh, A.J.W. (2000). In vivo treatment with GDF-9 stimulates primordial and primary follicle progression and theca cell marker CYP17 in ovaries of immature rats. Endocrinology 141, 3814–3820. https://doi.org/10.1210/endo.141.10.7732.

(2018). Test No. 443: Extended One-Generation Reproductive Toxicity Study (OECD).

List of Adverse Outcomes in this AOP

Event: 405: disrupted, ovarian cycle

Short Name: disrupted, ovarian cycle

Key Event Component

Process Object Action
ovulation cycle disrupted
ovulation cycle ovarian follicle disrupted

AOPs Including This Key Event

Biological Context

Level of Biological Organization
Individual

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
mice Mus sp. Low NCBI
rat Rattus norvegicus Moderate NCBI
Life Stage Applicability
Life Stage Evidence
Adult, reproductively mature
Sex Applicability
Sex Evidence
Female High

The estrous cycle comprises the recurring physiologic changes that are induced by reproductive hormones in most mammalian females. Many of the mechanisms involved in the regulation of the reproductive axis are similar across species (particularly those mediated through the estrogen receptor), assessments of rodent estrous cyclicity can offer insight into potential adverse effects in humans (Goldman, Murr, & Cooper, 2007). While evaluations of vaginal cytology in the laboratory rodent can provide a valuable reflection of the integrity of the hypothalamic-pituitary-ovarian axis, other indices are more useful in humans to determine the functional status of the reproductive system (e.g. menses, basal body temperature, alterations in vaginal pH, cervical mucous viscosity, and blood hormone levels). Nevertheless, since many of the mechanisms involved in the regulation of the reproductive axis are similar across species (particularly those mediated through the estrogen receptor), assessments of rodent estrous cyclicity can offer insight into potential adverse effects in humans (Rasier, Toppari, Parent, & Bourguignon, 2006).

Key Event Description

Biological state

The female ovarian cycle is the result of a balanced cooperation between several organs and is determined by a complex interaction of hormones. Ovarian cycle irregularities include disturbances in the ovarian cycle (e.g. longer cycle, persistent estrus) and/or ovulation problems (deferred ovulation or anovulation). The estrous cycle (also oestrous cycle) comprises the recurring physiologic changes that are induced by reproductive hormones in females. Estrous cycles start after sexual maturity in females and are interrupted by anestrous phases or pregnancies. During this cycle numerous well defined and sequential alterations in reproductive tract histology, physiology and cytology occur, initiated and regulated by the hypothalamic-pituitary-ovarian (HPO) axis. The central feature of the mammalian estrous cycle is the periodic maturation of eggs that will be released at ovulation and luteinisation of the follicles after ovulation to form corpora lutea. Adapted from www.oecd.org/chemicalsafety/testing/43754807.pdf Biological compartments

The cyclic changes that occur in the female reproductive tract are initiated and regulated by the hypothalamic-pituitary-ovarian (HPO) axis. Although folliculogenesis occurs independently of hormonal stimulation up until the formation of early tertiary follicles, the gonadotrophins luteinising hormone (LH) and follicle stimulating hormone (FSH) are essential for the completion of follicular maturation and development of mature preovulatory (Graafian) follicles. The oestrous cycle consists of four stages: prooestrus, oestrus, metoestrus (or dioestrus 1) and dioestrus (or dioestrus 2) orchestrated by hormones. Levels of LH and FSH begin to increase just after dioestrus. Both hormones are secreted by the same secretory cells (gonadotrophs) in the pars distalis of the anterior pituitary (adenohypophysis). FSH stimulates the development of the zona granulosa and triggers expression of LH receptors by granulosa cells. LH initiates the synthesis and secretion of androstenedione and, to a lesser extent, testosterone by the theca interna; these androgens are utilised by granulosa cells as substrates in the synthesis of estrogen. Pituitary release of gonadotrophins thus drives follicular maturation and secretion of estrogen during prooestrus. Gonadotrophin secretion by the anterior pituitary is regulated by luteinising hormone-releasing hormone (LHRH), produced by the hypothalamus. LHRH is transported along the axons of hypothalamic neurones to the median eminence where it is secreted into the hypothalamic-hypophyseal portal system and transported to the anterior pituitary. The hypothalamus secretes LHRH in rhythmic pulses; this pulsatility is essential for the normal activation of gonadotrophs and subsequent release of LH and FSH. Adapted from www.oecd.org/chemicalsafety/testing/43754807.pdf

Follicles that produce estrogens have sequestered pituitary FSH which in turn stimulates the aromatase reaction. Such follicles can undergo normal development and ovulation and contain eggs that readily resume meiosis when released. In the absence of an active local aromatase (i.e., no follicle-stimulating hormone), the follicles and oocytes become atretic and regress without ovulating. If aromatase is present, the estrogen and follicle stimulating hormone can further develop the follicular cells for normal luteal function after ovulation takes place (Ryan, 1982).

General role in biology

A sequential progression of interrelated physiological and behavioural cycles underlines the female's successful production of young. In many but not all species the first and most basic of these is estrous cycle, which is itself a combination of cycles.

How it is Measured or Detected

Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?


The pattern of events in the estrous cycle may provide a useful indicator of the normality of reproductive neuroendocrine and ovarian function in the nonpregnant female. It also provides a means to interpret hormonal, histologic, and morphologic measurements relative to stage of the cycle, and can be useful to monitor the status of mated females. Regular cyclicity is one of the key parameters in assessment of female reproductive function in rodents. Parameters assessed for cyclicity: - Number of cycling females - Number of females with regular cycles - Number of cycles - Estrous cycle length - Percentage of time spent in the various estrous cycle stages Estrous cyclicity provides a method for evaluating the endocrine disrupting activity of each test chemical under physiologic conditions where endogenous concentrations of estrogen vary. Abnormal cycles were defined as one or more estrous cycles in the 21-day period with prolonged estrus (≥3 days) and/or prolonged metestrus or diestrus (≥4 days) within a given cycle (Goldman, Murr, & Cooper, 2007).

Estrous cycle normality can be monitored in the rat and mouse by observing the changes in the vaginal smear cytology. Visual observation of the vagina is the quickest method, requires no special equipment, and is best used when only proestrus or estrus stages need to be identified. For details see: (Westwood, 2008), (Byers, Wiles, Dunn, & Taft, 2012) and OECD guidelines (www.oecd.org).

The observation that animals do not ovulate while exhibiting estrous cycles indicates that estrous cyclicity alone may not be a sufficient surrogate of healthy function of ovaries; the measurements of serum hormones and particularly FSH can contribute to more sensitivity indicators of healthy function of ovaries (Davis, Maronpot, & Heindel, 1994).

Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008) [1], (Test No. 416: Two-Generation Reproduction Toxicity, 2001)[2] and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) [3]and in USA EPA OCSPP 890.1450.

In vitro testing

The follicle culture models were developed for the in-vitro production of mature oocytes and used to study the process of folliculogenesis and oogenesis in vitro (Cortvrindt & Smitz, 2002). These in vitro cultures demonstrate near-identical effects to those found in vivo, therefore might be able to acquire a place in fertility testing, replacing some in-vivo studies for ovarian function and female gamete quality testing (Stefansdottir, Fowler, Powles-Glover, Anderson, & Spears, 2014).

Regulatory Significance of the AO

Chemicals may be found to interfere with reproductive function in the female rat. This interference is commonly expressed as a change in normal morphology of the reproductive tract or a disturbance in the duration of particular phases of the estrous cycle. This key event lies within the scope of testing for endocrine disrupting activity of chemicals and therefore for testing of female reproductive and developmental toxicity. Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008), (Test No. 416: Two-Generation Reproduction Toxicity, 2001) and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) and in USA EPA OCSPP 890.1450. While an evaluation of the estrous cycle in laboratory rodents can be a useful measure of the integrity of the hypothalamic-pituitary-ovarian reproductive axis, it can also serve as a way of insuring that animals exhibiting abnormal cycling patterns are excluded from a study prior to exposure to a test compound. When incorporated as an adjunct to other endpoint measures, a determination of a female's cycling status can contribute important information about the nature of a toxicant insult to the reproductive system. In doing so, it can help to integrate the data into a more comprehensive mechanistic portrait of the effect, and in terms of risk assessment, may provide some indication of a toxicant's impact on human reproductive physiology. Significant evidence that the estrous cycle (or menstrual cycle in primates) has been disrupted should be considered an adverse effect (OECD, 2008). Included should be evidence of abnormal cycle length or pattern, ovulation failure, or abnormal menstruation.

References

Byers, S. L., Wiles, M. V, Dunn, S. L., & Taft, R. A. (2012). Mouse estrous cycle identification tool and images. PloS One, 7(4), e35538. doi:10.1371/journal.pone.0035538

Cortvrindt, R. G., & Smitz, J. E. J. (2002). Follicle culture in reproductive toxicology: a tool for in-vitro testing of ovarian function? Human Reproduction Update, 8(3), 243–54.

Davis, B. J., Maronpot, R. R., & Heindel, J. J. (1994). Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicology and Applied Pharmacology, 128(2), 216–23. doi:10.1006/taap.1994.1200

Goldman, J. M., Murr, A. S., & Cooper, R. L. (2007). The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Research. Part B, Developmental and Reproductive Toxicology, 80(2), 84–97. doi:10.1002/bdrb.20106

OECD. (2008). No 43: Guidance document on mammalian reproductive toxicity testing and assessment.

Rasier, G., Toppari, J., Parent, A.-S., & Bourguignon, J.-P. (2006). Female sexual maturation and reproduction after prepubertal exposure to estrogens and endocrine disrupting chemicals: a review of rodent and human data. Molecular and Cellular Endocrinology, 254-255, 187–201. doi:10.1016/j.mce.2006.04.002

Ryan, K. J. (1982). Biochemistry of aromatase: significance to female reproductive physiology. Cancer Research, 42(8 Suppl), 3342s–3344s.

Stefansdottir, A., Fowler, P. A., Powles-Glover, N., Anderson, R. A., & Spears, N. (2014). Use of ovary culture techniques in reproductive toxicology. Reproductive Toxicology (Elmsford, N.Y.), 49C, 117–135. doi:10.1016/j.reprotox.2014.08.001

Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. (2008). OECD Publishing. doi:10.1787/9789264070684-en

Test No. 416: Two-Generation Reproduction Toxicity. (2001). OECD Publishing. doi:10.1787/9789264070868-en

Test No. 443: Extended One-Generation Reproductive Toxicity Study. (2012). OECD Publishing. doi:10.1787/9789264185371-en

Westwood, F. R. (2008). The female rat reproductive cycle: a practical histological guide to staging. Toxicologic Pathology, 36(3), 375–84. doi:10.1177/0192623308315665

Event: 406: decreased, Fertility

Short Name: decreased, Fertility

Key Event Component

Process Object Action
fertility decreased
fertilization fertility decreased

AOPs Including This Key Event

Biological Context

Level of Biological Organization
Individual

Domain of Applicability

Taxonomic Applicability
Term Scientific Term Evidence Links
rat Rattus norvegicus High NCBI
mouse Mus musculus High NCBI
human Homo sapiens High NCBI
Life Stage Applicability
Life Stage Evidence
Adult, reproductively mature High
Juvenile High
Adults High
Sex Applicability
Sex Evidence
Male High
Female High

Plausible domain of applicability

Taxonomic applicabilityThe impaired fertility may also have relevance for fish, mammals, amphibians, reptiles, birds and and invertebrates with sexual reproduction.

Life stage applicability: The impaired fertility can be measured at juveniles and adults.

Sex applicability: The impaired fertility can be measured in both male and female species. 

Key Event Description

Biological state

capability to produce offspring

Biological compartments

System

General role in biology

Fertility is the capacity to conceive or induce conception. Impairment of fertility represents disorders of male or female reproductive functions or capacity.

How it is Measured or Detected

As a measure, fertility rate, is the number of offspring born per mating pair, individual or population.

Regulatory Significance of the AO

Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (≥ 1000 t.p.a.).

Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) “reproductive toxicity” includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) “effects on fertility” includes adverse effects on sexual function and fertility; and c) “developmental toxicity” includes adverse effects on development of the offspring.

References

OECD (2001), Test No. 416: Two-Generation Reproduction Toxicity, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264070868-en.

OECD (2018), Test No. 443: Extended One-Generation Reproductive Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264185371-en.

OECD (2018), Test No. 414: Prenatal Developmental Toxicity Study, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264070820-en.

OECD (2018), "Reproduction/Developmental Toxicity Screening Test (OECD TG 421) and Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test (OECD TG 422)", in Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption, OECD Publishing, Paris, https://doi.org/10.1787/9789264304741-25-en.

Appendix 2

List of Key Event Relationships in the AOP